Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 9,251 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Kinetics Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Telavancin in Normal and Obese Subjects

NCT02753855
View directory record Official record
Conditions
Healthy
Interventions
Telavancin
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 8:13 PM EDT
Terminated Phase 1 Interventional

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

NCT02671955
View directory record Official record
Conditions
Advanced Cancer
Interventions
JNJ-61610588
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets

NCT01208155
View directory record Official record
Conditions
Bioavailability, Pharmacokinetics
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

NCT01290549
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Polatuzumab Vedotin, Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Stanford, California • Sarasota, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

NCT05856448
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GLPG3667, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Tucson, Arizona • La Jolla, California • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

NCT00432510
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
San Diego, California • Walnut Creek, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Retapamulin Microdialysis Feasibility Study

NCT01812382
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retapamulin Microdialysis
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

NCT01238796
View directory record Official record
Conditions
Kidney Diseases, End Stage Renal Disease
Interventions
telavancin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

NCT00717262
View directory record Official record
Conditions
Healthy
Interventions
HQK-1001, placebo
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 15, 2009 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

NCT01451424
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami Gardens, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Jun 10, 2026, 8:13 PM EDT
Terminated Phase 3 Interventional

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05288855
View directory record Official record
Conditions
Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Interventions
Voclosporin, Placebo Oral Capsule
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 4 Interventional

PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients

NCT00178425
View directory record Official record
Conditions
Transplantation, Liver
Interventions
Serial blood sampling as described in protocol, Estimation of Creatinine Clearance at regular intervals
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2007 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01001442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BT062
Drug
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

NCT07170189
View directory record Official record
Conditions
Overweight
Interventions
HU6
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Results available

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

NCT04900974
View directory record Official record
Conditions
HIV Infections, Pregnancy Related
Interventions
Doravirine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

NCT01410227
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII)
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 2 Interventional

The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients

NCT00080574
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Skin Biopsy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

NCT00740610
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
GS-9450, GS-9450 Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
31
States / cities
Tucson, Arizona • Fresno, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Jun 10, 2026, 8:13 PM EDT
Recruiting Phase 1 Interventional

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT04222413
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Interventions
Metarrestin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Fairway, Kansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

SB-743921 In Patients With Solid Tumors

NCT00136513
View directory record Official record
Conditions
Solid Tumor Cancer
Interventions
SB-743921
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

NCT00650910
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, Digoxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

NCT04571424
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB133 (Dapirolizumab pegol), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

NCT01165580
View directory record Official record
Conditions
Cytomegalovirus Infections, Heart Transplantation
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 124 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 8:13 PM EDT